SHC Stock Analysis: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$14.96
0.09 (0.61%)
ā²
5d:
+10.49%
30d:
-5.08%
90d:
-15.19%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 07, 2026
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ā BUY SIGNAL: SHC appears deeply undervalued. Market expects -6.0% annual earnings decline despite 175% recent earnings growth. Contrarian opportunity at discount to historical valuation.
ā BUY SIGNAL: SHC appears deeply undervalued. Market expects -6.0% annual earnings decline despite 175% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.42
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$15.16
1.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $14.96, which is considered fair relative to its 30-day fair value range of $13.39 to $15.79. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.3) compared to its historical average (17.2). Remarkably, the market is currently pricing in an annual earnings decline of 6.0% over the next few years. This pessimistic expectation contrasts with the company's recent 175.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $15.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SHC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.75 (+38.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $15.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SHC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.75 (+38.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$13.39 -
$15.79
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.7% below Wall St target ($20.75)
Fair Price Analysis
30-Day Fair Range
$13.39 -
$15.79
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$13.09
Resistance Level
$15.10
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.29
Wall Street Target
$20.75
(+38.7%)
Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
175.4%
Profit Margin
6.7%
Valuation Discount vs History
-6.0% cheaper
PE vs Historical
14.3 vs 17.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.0%
(market-implied from PE analysis)
1-Year Target
$14.06
(-6%)
2-Year Target
$13.22
(-12%)
3-Year Target
$12.43
(-17%)
3-Yr Target (if PE normalizes)
(PE: 14ā17)
$14.95
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 8.6%)
$27.61
(+85%)
Base:
(SPY PE: 14.3, Growth: 8.6%)
$19.19
(+28%)
Bear:
(PE: 12.1, Growth: 8.6%)
$16.31
(+9%)
š
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (50x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 50.00 | Current EPS (TTM): $0.27
Bull Case
$29.70
(+114%)
Analyst growth 100.0%, PE expands to 55.0
Base Case
$27.00
(+95%)
Market implied 100.0%, PE stable at 50.0
Bear Case
$9.18
(-34%)
Severe decline -20.0%, PE contracts to 42.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
š”
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.3 to 17.2
Stabilization Target:
$18.00
(+20.3%)
PE Expansion Potential:
+20.3%
Share & Embed Analysis
Last updated: April 02, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Gtcr Investment Xi Llc
SELL
10000000 shares
2026-03-06
Michael B Jr. Petras
SELL
315896 shares
2025-12-08
Michael B Jr. Petras
SELL
434104 shares
2025-12-08
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientificā¦ |
STRONG BUY
31 analysts |
$664 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 67 BUY |
|
EXAS
EXACT Sciences Corporatiā¦ |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 62 BUY |
